Advances in the Early Detection of Lung Cancer using Analysis of Volatile Organic Compounds: From Imaging to Sensors

Li, Wang; Liu, Hongying; Jia, Ziru; Qiao, Panpan; Pi, Xiaodong; Deng, Linhong

doi:10.7314/apjcp.2014.15.11.4377

Cited by 29 publications

(18 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cystoscopy-aided biopsy and histopathological confirmation remain the goldstandard against which several biomarkers have been tested in the past [2]. Disease-specific volatile organic compounds (VOCs) in the form of cancer biomarkers provide a new exciting perspective for early cancer detection in urinary bladder and other site cancers [3,4].…”

Section: Introductionmentioning

confidence: 99%

Optical sensory arrays for the detection of urinary bladder cancer‐related volatile organic compounds

Zhu

Corsetti

Wang

et al. 2019

Journal of Biophotonics

View full text Add to dashboard Cite

Non-invasive detection of urinary bladder cancer remains a significant challenge. Urinary volatile organic compounds (VOCs) are a promising alternative to cell-based biomarkers. Herein, we demonstrate a novel diagnosis system based on an optic fluorescence sensor array for detecting urinary bladder cancer VOCs biomarkers. This study describes a fluorescence-based VOCs sensor array detecting system in detail. The choice of VOCs for the initial part was based on an extensive systematic search of the literature and then followed up using urinary samples from patients with urinary bladder transitional cell carcinoma. Canonical discriminant analysis (CDA) and partial least squares discriminant analysis (PLS-DA) was employed and correctly detected 31/48 urinary bladder cancer VOC biomarkers and achieved an overall 77.75% sensitivity and 93.25% specificity by PLS-DA modelling. All five urine samples from bladder cancer patients and five healthy controls were successfully identified with the same sensor arrays. Overall, the experiments in this study describe a real-time platform for non-invasive bladder cancer diagnosis using fluorescence-based gas-sensor arrays. Pure VOCs and urine samples from the patients proved such a system to be promising, however further research is required using a larger population sample. This article is protected by copyright. All rights reserved.

show abstract

Section: Introductionmentioning

confidence: 99%

Optical sensory arrays for the detection of urinary bladder cancer‐related volatile organic compounds

Zhu

Corsetti

Wang

et al. 2019

Journal of Biophotonics

View full text Add to dashboard Cite

show abstract

“…Experiments have been performed using different technologies, such as gas chromatography, spectrometry, spectroscopy, electronic noses (eg, quartz crystal microbalance, surface acoustic wave sensors, gold nanoparticle sensors, colorimetric sensors), and even canine scent detection, for differentiating VOCs in patients with LC compared with healthy controls. 66 Phillips et al performed VOC analyses using gas chromatography and mass spectrometry and demonstrated a sensitivity of 84.6% and a specificity of 80%. 67 Ehmann et al demonstrated that, when exhaled breath was presented to sniffer dogs, LC was identified with an overall sensitivity of 71% and a specificity of 93% independent of the presence of chronic obstructive pulmonary disease or tobacco smoke.…”

Section: Volatile Organic Compoundsmentioning

confidence: 99%

“…According to the hypothesis of oxidative stress, breath VOCs reflect the biochemical status of the body, with the potential to aid in early LC detection. Experiments have been performed using different technologies, such as gas chromatography, spectrometry, spectroscopy, electronic noses (eg, quartz crystal microbalance, surface acoustic wave sensors, gold nanoparticle sensors, colorimetric sensors), and even canine scent detection, for differentiating VOCs in patients with LC compared with healthy controls . Phillips et al performed VOC analyses using gas chromatography and mass spectrometry and demonstrated a sensitivity of 84.6% and a specificity of 80% .…”

Section: Introductionmentioning

confidence: 99%

Screening and early detection efforts in lung cancer

Kanodra

Silvestri

Tanner

2015

Cancer

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related death in the United States. Since publication of results from the National Lung Screening Trial, several professional organizations, including the US Preventive Services Task Force, have published guidelines recommending low-dose computed tomography for screening in asymptomatic, high-risk individuals. The benefits of screening include detection of cancer at an early stage when a definitive cure is possible, but the risks include overdiagnosis, false-positive results, psychological distress, and radiation exposure. The current review covers the scope of low-dose computed tomography screening, potential risks, costs, and future directions in the efforts for early detection of lung cancer. Cancer 2015;121:1347-56. V C 2015 American Cancer Society.KEYWORDS: cancer screening, lung neoplasms, risk assessment, early detection. INTRODUCTIONLung cancer (LC) is the second most common cancer among both men and women in the United States and accounts for more deaths than any other cancer. 1 The 5-year survival rate for LC remains low at 16.8% and is <5% for patients with metastatic disesae. 2 The utility of sputum cytology and chest radiographs alone and in combination has been extensively studied and has not exhibited any benefit as a screening tool. 3,4 Several single-arm trials have suggested that screening with computed tomography (CT) may be of benefit 5 ; however, it was not until the publication of the National Lung Screening Trial (NLST) in 2010 that strong evidence was available in support of LC screening. 6 The results of the NLST lead to several professional societies supporting LC screening for individuals at high risk. 6,7 The US Preventive Services Task Force (USPSTF) guidelines gave a Grade B recommendation for LC screening using annual low-dose CT (LDCT) in high-risk individuals. 8 Since publication of the NLST, additional studies have been completed that further refine an individual's risk, thereby identifying the best candidates for screening. 9,10 This review focuses on current recommendations for LC screening, including risks, benefits, costs, and future directions in the efforts for early detection.

show abstract

“…In the past decades, several artificial olfaction systems (i.e., e-nose technology) based on nonselective chemical sensors aimed at measuring and comparing VOC patterns (breathprint) have been proposed in the literature to obtain a precise identification of the compounds observed in exhaled breath of lung cancer patients. 38,59 Such technologies differ from each other in a E-nose based on colorimetric sensor array technology; C-statistic for the distinction between adenocarcinoma and squamous cell ¼ 0.864. 26,67,82 Adca, adenocarcinoma; Squam, squamous cell carcinoma; GC-MS, gas chromatography-mass spectrometry.…”

Section: Results Of Breathprinting For Early Diagnosis Of Lung Cancermentioning

confidence: 99%

Breathprinting and Early Diagnosis of Lung Cancer

Rocco

Pennazza

Santonico

et al. 2018

Journal of Thoracic Oncology

View full text Add to dashboard Cite

The electronic nose (e-nose) is a promising technology as a useful addition to the currently available modalities to achieve lung cancer diagnosis. The e-nose can assess the volatile organic compounds detected in the breath and derived from the cellular metabolism. Volatile organic compounds can be analyzed to identify the individual chemical elements as well as their pattern of expression to reproduce a sensorial combination similar to a fingerprint (breathprint). The e-nose can be used alone, mimicking the combinatorial selectivity of the human olfactory system, or as part of a multisensorial platform. This review analyzes the progress made by investigators interested in this technology as well as the perspectives for its future utilization.

show abstract

Advances in the Early Detection of Lung Cancer using Analysis of Volatile Organic Compounds: From Imaging to Sensors

Cited by 29 publications

References 84 publications

Optical sensory arrays for the detection of urinary bladder cancer‐related volatile organic compounds

Optical sensory arrays for the detection of urinary bladder cancer‐related volatile organic compounds

Screening and early detection efforts in lung cancer

Breathprinting and Early Diagnosis of Lung Cancer

Contact Info

Product

Resources

About